{ "kind": "framework", "value": "clinical-trial-design", "collectionKey": "slides:framework:clinical-trial-design:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 129, "page": 1, "pageSize": 24, "pageCount": 6, "rows": [ { "docId": "019de072-0fef-7225-bee8-4eafefc8a1ee", "docSlug": "7f14a86c142f5693f0e80c8dcf59a0d2", "documentTitle": "23andMe | Investor Presentation Deck | 63 slides", "authorId": "23andme", "authorName": "23andMe", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-02-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide outlines a standard clinical trial design including patient criteria, cohort structure (Part A/B), and primary/secondary objectives.", "imagePath": null, "matchCount": 1, "evidence": "Standardized structure for Phase 1 study methodology", "slideHref": "/slides/019de072-0fef-7225-bee8-4eafefc8a1ee/47", "deckHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee", "deckAnchorHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee#slide-47", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de070-182a-72ba-952e-2b048c610e12", "docSlug": "cea7bfa85dc209a87c7b2adf6cd4697f", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2020-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide outlines a randomized controlled trial structure with an open-label extension.", "imagePath": null, "matchCount": 1, "evidence": "Standardized representation of patient cohorts, randomization, and study phases.", "slideHref": "/slides/019de070-182a-72ba-952e-2b048c610e12/11", "deckHref": "/decks/019de070-182a-72ba-952e-2b048c610e12", "deckAnchorHref": "/decks/019de070-182a-72ba-952e-2b048c610e12#slide-11", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de070-3a76-76eb-bdcd-70a194f2629a", "docSlug": "3b5651eafaa236908b5aaeea5fdc2dcc", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2020-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide uses a process flow diagram to illustrate the clinical trial phases.", "imagePath": null, "matchCount": 1, "evidence": "The slide outlines the structure of a Phase 3 clinical trial including randomization, arms, and endpoints.", "slideHref": "/slides/019de070-3a76-76eb-bdcd-70a194f2629a/13", "deckHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a", "deckAnchorHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a#slide-13", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de072-122c-721c-8b62-3522a74ffc66", "docSlug": "bcca0cb7dade19d9f637477238714c68", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 33 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-02-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "other", "function": "present_framework", "notes": "The slide uses a process flow diagram to illustrate the clinical trial structure.", "imagePath": null, "matchCount": 1, "evidence": "Standardized representation of patient flow, randomization, and endpoints in a clinical study.", "slideHref": "/slides/019de072-122c-721c-8b62-3522a74ffc66/22", "deckHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66", "deckAnchorHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66#slide-22", "loopMatches": [ { "to": 26, "from": 21, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "9cc0cacb-1c5c-40f5-a519-d219894ab0a2", "evidence": "The deck provides clinical data supporting the effectiveness of Pegzilarginase", "position": 1, "objective": "Show the potential of Pegzilarginase to improve patient outcomes", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-d756-7568-8588-410684bab010", "docSlug": "c18c99fc10f671fc397f8a743cdc0ce4", "documentTitle": "Aeglea BioTherapeutics | Results Presentation Deck | 23 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Aeglea BioTherapeutics", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide uses a process flow diagram to illustrate the clinical trial phases (randomization, treatment, extension).", "imagePath": null, "matchCount": 1, "evidence": "Standardized representation of patient randomization and study arms.", "slideHref": "/slides/019de071-d756-7568-8588-410684bab010/6", "deckHref": "/decks/019de071-d756-7568-8588-410684bab010", "deckAnchorHref": "/decks/019de071-d756-7568-8588-410684bab010#slide-6", "loopMatches": [ { "to": 15, "from": 5, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "81d36eb9-c56a-4571-9f51-feb9c7f6295f", "evidence": "Presents Pegzilarginase's benefits in managing arginine levels and improving patient outcomes.", "position": 1, "objective": "Demonstrates how Pegzilarginase meets the need for effective arginine reduction", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 10, "from": 5, "beatId": "e0d16f2c-c175-4c6a-8d80-f841a8242c55", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Slides present Pegzilarginase's efficacy in reducing arginine levels and improving mobility.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-38a0-778d-8d39-45a206af86ac", "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e", "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-07-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide outlines a clinical trial protocol involving 180 patients, stratified by condition and severity, with a 26-week duration and specific primary/secondary endpoints.", "imagePath": null, "matchCount": 1, "evidence": "The slide describes a standard clinical trial protocol structure including patient population, stratification, treatment arms, and endpoints.", "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/36", "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac", "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-36", "loopMatches": [ { "to": 43, "from": 29, "name": "Aha Moment", "slug": "03-aha-moment", "bestFor": "Data-heavy sections, research findings, analytical arguments", "matchId": "2d58beec-e58f-42d6-98ee-47f2b7cb1adf", "evidence": "Data presentation and analysis", "position": 1, "objective": "Reveal the potential of Efgartigimod", "structure": "The Problem/Question -> What the Data Shows -> The Insight", "confidence": 0.8, "description": "Establish a tension, present data, then deliver the insight that changes everything" } ], "arcBeatMatches": [ { "to": 43, "from": 29, "beatId": "002ee641-6d99-4db6-a151-22313bbe3e4f", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Data supporting Efgartigimod's effectiveness", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-38a0-778d-8d39-45a206af86ac", "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e", "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-07-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "other", "function": "present_framework", "notes": "Clinical trial design diagram showing a 1:1 randomization between Efgartigimod and Placebo over 36 weeks.", "imagePath": null, "matchCount": 1, "evidence": "Standardized representation of patient population, intervention, and endpoints.", "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/45", "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac", "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-45", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-94a0-75ef-b86b-e4894fa7dc1d", "docSlug": "8b4d61768a47893d5f24ee0f1f9ae717", "documentTitle": "argenx SE | Results Presentation Deck | 20 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "other", "function": "present_framework", "notes": "The slide outlines a parallel clinical trial structure for IV and SC administration of efgartigimod.", "imagePath": null, "matchCount": 1, "evidence": "Visual representation of trial phases and dosing schedules", "slideHref": "/slides/019de071-94a0-75ef-b86b-e4894fa7dc1d/7", "deckHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d", "deckAnchorHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 7, "beatId": "3c157cf2-a15a-4adb-bf74-d8b7db4a16f5", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-3", "evidence": "The roadmap slides present the current pipeline and development plans", "position": 2, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de070-c935-736b-bfac-0e59550f8f0f", "docSlug": "bbdd6d1004c11d68b286eff6aee60dc0", "documentTitle": "argenx SE | Results Presentation Deck | 20 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "roadmap", "function": "present_framework", "notes": "The slide outlines a multi-stage clinical trial process including a Go/No Go decision point.", "imagePath": null, "matchCount": 1, "evidence": "The slide maps out the phases and stages of a clinical trial (screening, run-in, treatment).", "slideHref": "/slides/019de070-c935-736b-bfac-0e59550f8f0f/8", "deckHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f", "deckAnchorHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f#slide-8", "loopMatches": [ { "to": 10, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "9f6093ef-7c49-4bf6-8291-96e05249086f", "evidence": "The presentation presents several clinical trials and pipeline opportunities", "position": 1, "objective": "Highlight the potential of efgartigimod in various indications", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 10, "from": 4, "beatId": "370e7a7b-342c-4314-a537-20aca17005f0", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation highlights the company's promising pipeline and clinical trials", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de070-c935-736b-bfac-0e59550f8f0f", "docSlug": "bbdd6d1004c11d68b286eff6aee60dc0", "documentTitle": "argenx SE | Results Presentation Deck | 20 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "other", "function": "present_framework", "notes": "The slide outlines the dosing schedule (weeks 1-4, 5-16, and beyond) and the primary objective for the trials.", "imagePath": null, "matchCount": 1, "evidence": "The slide maps out the patient population, intervention arms, and primary endpoint of a clinical study.", "slideHref": "/slides/019de070-c935-736b-bfac-0e59550f8f0f/9", "deckHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f", "deckAnchorHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f#slide-9", "loopMatches": [ { "to": 10, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "9f6093ef-7c49-4bf6-8291-96e05249086f", "evidence": "The presentation presents several clinical trials and pipeline opportunities", "position": 1, "objective": "Highlight the potential of efgartigimod in various indications", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 10, "from": 4, "beatId": "370e7a7b-342c-4314-a537-20aca17005f0", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation highlights the company's promising pipeline and clinical trials", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de070-c935-736b-bfac-0e59550f8f0f", "docSlug": "bbdd6d1004c11d68b286eff6aee60dc0", "documentTitle": "argenx SE | Results Presentation Deck | 20 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "other", "function": "present_framework", "notes": "The slide uses a process flow diagram to illustrate the clinical trial protocol.", "imagePath": null, "matchCount": 1, "evidence": "The slide outlines the methodology and structure of a Phase 3 clinical trial.", "slideHref": "/slides/019de070-c935-736b-bfac-0e59550f8f0f/10", "deckHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f", "deckAnchorHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f#slide-10", "loopMatches": [ { "to": 10, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "9f6093ef-7c49-4bf6-8291-96e05249086f", "evidence": "The presentation presents several clinical trials and pipeline opportunities", "position": 1, "objective": "Highlight the potential of efgartigimod in various indications", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 10, "from": 4, "beatId": "370e7a7b-342c-4314-a537-20aca17005f0", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation highlights the company's promising pipeline and clinical trials", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-753f-7227-aa1d-36a319c59353", "docSlug": "7013d0966bfedd0d757b9fa24a480455", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "appendix_methodology", "function": "present_framework", "notes": "Clinical trial design diagram showing patient flow from enrollment to treatment arms.", "imagePath": null, "matchCount": 1, "evidence": "Standardized representation of patient flow and treatment arms in a clinical study.", "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/32", "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353", "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de072-1970-7036-9d15-9ffed6304914", "docSlug": "3db8307bc8c7b92a71fc075519a1ccaf", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 35 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-02-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide uses a standard clinical trial flow diagram (CONSORT-style).", "imagePath": null, "matchCount": 1, "evidence": "Standard CONSORT-style flow diagram for clinical trial methodology", "slideHref": "/slides/019de072-1970-7036-9d15-9ffed6304914/10", "deckHref": "/decks/019de072-1970-7036-9d15-9ffed6304914", "deckAnchorHref": "/decks/019de072-1970-7036-9d15-9ffed6304914#slide-10", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-f579-76ad-bea5-b34da2c83a75", "docSlug": "563487226462eb4ab63630eb9b74a5cf", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide uses a standard clinical trial flow diagram (randomization process).", "imagePath": null, "matchCount": 1, "evidence": "Standardized flow diagram for clinical trial methodology", "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/10", "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75", "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 9, "beatId": "5bf1753c-e4a0-4e18-b568-73af9c0043f2", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The deck presents data and results for Imfinzi TOPAZ-1 and HIMALAYA, demonstrating their effectiveness", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-f579-76ad-bea5-b34da2c83a75", "docSlug": "563487226462eb4ab63630eb9b74a5cf", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "other", "function": "present_framework", "notes": "The slide uses a standard clinical trial flow diagram (CONSORT-style).", "imagePath": null, "matchCount": 1, "evidence": "Standardized representation of patient randomization and study objectives.", "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/18", "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75", "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 9, "beatId": "5bf1753c-e4a0-4e18-b568-73af9c0043f2", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The deck presents data and results for Imfinzi TOPAZ-1 and HIMALAYA, demonstrating their effectiveness", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-dd7f-730a-8977-e46a36e30dcf", "docSlug": "abc22aebd2d55a5159142df321cabcee", "documentTitle": "Bionomics | IPO Presentation Deck | 38 slides", "authorId": "bionomics", "authorName": "Bionomics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2021-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7391304, "pageNumber": 15, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "Includes clinical trial design flow chart and regulatory milestones.", "imagePath": null, "matchCount": 1, "evidence": "Flowchart showing screening, randomization, and endpoints", "slideHref": "/slides/019de071-dd7f-730a-8977-e46a36e30dcf/15", "deckHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf", "deckAnchorHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf#slide-15", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-dd7f-730a-8977-e46a36e30dcf", "docSlug": "abc22aebd2d55a5159142df321cabcee", "documentTitle": "Bionomics | IPO Presentation Deck | 38 slides", "authorId": "bionomics", "authorName": "Bionomics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2021-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7391304, "pageNumber": 34, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide uses a structured table-like layout to present clinical trial parameters.", "imagePath": null, "matchCount": 1, "evidence": "Standardized presentation of trial parameters (design, criteria, objectives)", "slideHref": "/slides/019de071-dd7f-730a-8977-e46a36e30dcf/34", "deckHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf", "deckAnchorHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6", "docSlug": "58255c61d2bdadc3239a5fe01efc41e1", "documentTitle": "BioNTech | Results Presentation Deck | 43 slides", "authorId": "biontech", "authorName": "BioNTech", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "other", "function": "present_framework", "notes": "Clinical trial design diagram showing randomization of 120 patients into three arms.", "imagePath": null, "matchCount": 1, "evidence": "Standardized representation of patient randomization and study arms", "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/25", "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6", "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-25", "loopMatches": [ { "to": 42, "from": 7, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836", "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements", "position": 0, "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 25, "from": 15, "beatId": "53c149a8-57e4-41f6-bcc6-f6d3b92e5c06", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents BioNTech's product portfolio, including its COVID-19 vaccine and pipeline candidates", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de070-5bad-7209-9a4b-c2388bb12878", "docSlug": "45a794600ccc29f3eaf009a5452211e7", "documentTitle": "Codiak | IPO Presentation Deck | 36 slides", "authorId": "codiak", "authorName": "Codiak", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2020-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide outlines a standard oncology clinical trial structure with a 3+3 dose escalation design and specific target indications for expansion.", "imagePath": null, "matchCount": 1, "evidence": "3+3 dose escalation and expansion cohort structure", "slideHref": "/slides/019de070-5bad-7209-9a4b-c2388bb12878/23", "deckHref": "/decks/019de070-5bad-7209-9a4b-c2388bb12878", "deckAnchorHref": "/decks/019de070-5bad-7209-9a4b-c2388bb12878#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 35, "from": 16, "beatId": "87a4caff-9c60-44c7-b0ac-0079e1a8e9eb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "Slides 16-35 outline Codiak's pipeline, clinical programs, and future plans", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-eb84-776b-8e7d-ce40a476afec", "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02", "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides", "authorId": "kymera", "authorName": "Kymera", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide outlines a clinical trial methodology involving healthy volunteers (HV) and patients across SAD and MAD cohorts.", "imagePath": null, "matchCount": 1, "evidence": "Structure of SAD/MAD cohorts and endpoints", "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/26", "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec", "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-eb84-776b-8e7d-ce40a476afec", "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02", "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides", "authorId": "kymera", "authorName": "Kymera", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 55, "slideType": "other", "function": "present_framework", "notes": "The diagram illustrates a multi-arm clinical trial design with dose escalation (DL1, DL2, DLx) leading to MTD/RP2D expansion cohorts for various indications, including combination therapy arms.", "imagePath": null, "matchCount": 1, "evidence": "The slide maps out the progression of a clinical trial from dose escalation to expansion cohorts.", "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/55", "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec", "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-55", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b97-5cb48bf2a635", "docSlug": "b8afd3741673", "documentTitle": "Chinook Therapeutics Inc (KDNY)", "authorId": "51_Muddy_Waters", "authorName": "Carson C. Block", "documentKindSlug": "research-note", "documentKindLabel": "Research note", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2023-05-16 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 34, "slideType": "executive_summary", "function": "establish_context", "notes": "Includes detailed diagrams of disease pathophysiology and clinical trial design.", "imagePath": null, "matchCount": 1, "evidence": "Study design timeline and inclusion criteria", "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/34", "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635", "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-473e-712d-87f0-b99471a2308d", "docSlug": "b8bc6e04b9c70160cc1bc532a2ac4eea", "documentTitle": "Nuvalent | IPO Presentation Deck | 40 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2021-07-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7827299, "pageNumber": 23, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a hybrid layout combining a staircase diagram for Phase 1 and a structured table for Phase 2.", "imagePath": null, "matchCount": 1, "evidence": "Structured cohort breakdown for regulatory registration", "slideHref": "/slides/019de071-473e-712d-87f0-b99471a2308d/23", "deckHref": "/decks/019de071-473e-712d-87f0-b99471a2308d", "deckAnchorHref": "/decks/019de071-473e-712d-87f0-b99471a2308d#slide-23", "loopMatches": [ { "to": 23, "from": 22, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "eb06e03e-4835-4d57-9906-4c725d518b80", "evidence": "The document presents the planned clinical trial as a significant milestone.", "position": 1, "objective": "Present the planned NVL-520 first-in-human clinical trial", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.7, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-7055-71be-8e36-ff3241c1e380", "docSlug": "06f5a1d0d7573c1d13069d999ff5f2e2", "documentTitle": "RenovoRx | IPO Presentation Deck | 29 slides", "authorId": "renovorx", "authorName": "RenovoRx", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2021-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7843866, "pageNumber": 25, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide outlines a clinical trial protocol including induction, randomization, and primary endpoint.", "imagePath": null, "matchCount": 1, "evidence": "The slide depicts a standard randomized controlled trial (RCT) flow.", "slideHref": "/slides/019de071-7055-71be-8e36-ff3241c1e380/25", "deckHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380", "deckAnchorHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380#slide-25", "loopMatches": [ { "to": 28, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "eeb5d12f-412a-4325-8fbd-2a39f305b6d7", "evidence": "Slides 4 and 28 present the executive summary and investment highlights", "position": 1, "objective": "Present the investment highlights and ask", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }